Latest Articles

Publication Date
Associations between body mass index and retained placenta in delivery hospitalizations: Analysis of the Nationwide Inpatient Sample, 2016-2020.

Retained placenta (RP) is an obstetric complication associated with postpartum hemorrhage, sepsis, and maternal morbidity. While maternal body mass index (BMI) influences pregnancy outcomes, its associations with RP are unclear. …

Published: July 22, 2026, midnight
Mendelian randomization of risk factors for premenstrual disorders.

The causal role of established risk factors for premenstrual disorders (PMDs) remains unclear. We used Mendelian randomization (MR) to assess causality for eight known-risk factors identified through a literature review. …

Published: July 16, 2026, midnight
Association between endometriosis and chronic endometritis: A retrospective cross-sectional study.

Chronic endometritis (CE) is a plasma cell-related endometrial inflammatory phenotype that may compromise fertility, while endometriosis (EM) is an immune-mediated inflammatory disorder. However, whether EM is associated with CD138-defined CE …

Published: June 29, 2026, midnight
Diagnostic Accuracy of Hysterosalpingography Compared With Laparoscopy in Assessing Tubal Patency Among Subfertile Women: A Retrospective Cohort Study.

Background Fallopian tube pathology accounts for approximately one-third of female factor subfertility. The National Institute for Health and Care Excellence (NICE) Fertility Guidelines (CG156) recommend hysterosalpingography (HSG) as the first-line …

Published: June 13, 2026, midnight
Medicus Pharma Submits Ind Application for PRECISION-E2 Phase 2A Study of Teverelix in Endometriosis in United Arab Emirates - marketscreener.com

Medicus Pharma Submits Ind Application for PRECISION-E2 Phase 2A Study of Teverelix in Endometriosis in United Arab Emirates marketscreener.com

Published: June 11, 2026, 1:52 p.m.
Medicus Pharma submits IND application for endometriosis trial By Investing.com - Investing.com Nigeria

Medicus Pharma submits IND application for endometriosis trial By Investing.com Investing.com Nigeria

Published: June 11, 2026, 11:58 a.m.
Medicus Pharma submits IND application for endometriosis trial - Investing.com

Medicus Pharma submits IND application for endometriosis trial Investing.com

Published: June 11, 2026, 11:55 a.m.
Medicus Pharma submits IND application for endometriosis trial By Investing.com - Investing.com Canada

Medicus Pharma submits IND application for endometriosis trial By Investing.com Investing.com Canada

Published: June 11, 2026, 11:41 a.m.
Medicus Pharma Ltd. Submits IND Application for Innovative PRECISION-E2 Phase 2a Clinical Trial in Endometriosis - Quiver Quantitative

Medicus Pharma Ltd. Submits IND Application for Innovative PRECISION-E2 Phase 2a Clinical Trial in Endometriosis Quiver Quantitative

Published: June 11, 2026, 11:41 a.m.
Medicus Pharma submits endometriosis IND in Abu Dhabi - grafa.com

Medicus Pharma submits endometriosis IND in Abu Dhabi grafa.com

Published: June 11, 2026, 8 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!